Inhibition of aggrecan turnover in short-term explant cultures of bovine tendon

Matrix Biology

Volumn 26, Issue 4, 2007, Pages 280-290

  Rees, Sarah G ^a   Waggett, Andrew D ^b   Dent, Colin M ^c   Caterson, Bruce ^b  

^a SWANSEA UNIVERSITY   (United Kingdom)

^b CARDIFF UNIVERSITY   (United Kingdom)

^c CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Aggrecan; Aggrecanases; Matrix metalloproteinases; Proteoglycan; Tendon

Indexed keywords

ACTINONIN; AGGRECAN; AGGRECANASE INHIBITOR; COLLAGEN FIBER; INTERSTITIAL COLLAGENASE; MARIMISTAT; MATRIX METALLOPROTEINASE INHIBITOR; UNCLASSIFIED DRUG; WATER;

ANIMAL TISSUE; ARTHRITIS; ARTICLE; CANCER; CATABOLISM; COMPRESSIVE STRENGTH; CULTURE MEDIUM; EXPLANT; IMMUNOHISTOCHEMISTRY; METABOLITE; NONHUMAN; PRIORITY JOURNAL; TENDON;

AGGRECANS; ANIMALS; CARTILAGE; CATTLE; CELL CULTURE TECHNIQUES; COLLAGEN; CULTURE MEDIA; ENDOPEPTIDASES; ENZYME INHIBITORS; EXTRACELLULAR MATRIX PROTEINS; MATRIX METALLOPROTEINASES; MOLECULAR SEQUENCE DATA; PROTEOGLYCANS; TENDONS;

BOVINAE;

EID: 34247484013     PISSN: 0945053X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.matbio.2007.01.003     Document Type: Article

References (48)

1. Benjamin M., and Ralphs J.R. Functional and developmental anatomy of tendons and ligaments. In: Gordon S.L., Blair S.J., and Fine L.J. (Eds). Repetitive Motion Disorders of the Upper Extremity (1995), American Academy of Orthopaedic Surgeons, Rosemont, ILL 185-203
2. Berenson M.C., Blevins F.T., Plaas A.H., and Vogel K.G. Proteoglycans of human rotator cuff tendons. J. Orthop. Res. 14 (1996) 518-525
3. Caterson B., Christner J.E., Baker J.R., and Couchman J.R. Production and characterization of monoclonal antibodies directed against connective tissue proteoglycans. Fed. Proc. 44 (1985) 386-393
4. Caterson B., Hughes C.E., Roughley P., and Mort J.S. Anabolic and catabolic markers of proteoglycan metabolism in osteoarthritis. Acta Orthop. Scand., Suppl. 266 (1995) 121-124
5. Corps A.N., Robinson A.H., Movin T., Costa M.L., Ireland D.C., Hazleman B.L., and Riley G.P. Versican splice variant messenger RNA expression in normal human Achilles tendon and tendinopathies. Rheumatology (Oxford) 43 (2004) 969-972
6. Corps A.N., Robinson A.H., Movin T., Costa M.L., Hazleman B.L., and Riley G.P. Increased expression of aggrecan and biglycan mRNA in Achilles tendinopathy. Rheumatology (Oxford) 45 (2006) 291-294
7. Drummond A.H., Beckett P., Brown P.D., Bone E.A., Davidson A.H., Galloway W.A., Gearing A.J., Huxley P., Laber D., McCourt M., Whittaker M., Wood L.M., and Wright A. Preclinical and clinical studies of MMP inhibitors in cancer. Ann. N. Y. Acad. Sci. 878 (1999) 228-235
8. Farndale R.W., Buttle D.J., and Barrett A.J. Improved quantitation and discrimination of sulphated glycosaminoglycans by use of dimethylmethylene blue. Biochim. Biophys. Acta 883 (1986) 173-177
9. Gao G., Westling J., Thompson V.P., Howell T.D., Gottschall P.E., and Sandy J.D. Activation of the proteolytic activity of ADAMTS4 (aggrecanase-1) by C-terminal truncation. J. Biol. Chem. 277 (2002) 11034-11041
10. Gillard G.C., Merrilees M.J., Bell-Booth P.G., Reilly H.C., and Flint M.H. The proteoglycan content and the axial periodicity of collagen in tendon. Biochem. J. 163 (1977) 145-151
11. Gillard G.C., Reilly H.C., Bell-Booth P.G., and Flint M.H. The influence of mechanical forces on the glycosaminoglycan content of the rabbit flexor digitorum profundus tendon. Connect. Tissue Res. 7 (1979) 37-46
12. Handley C.J., and Campbell M.A. Catabolism and turnover of proteoglycans. Methods Enzymol. 144 (1987) 412-419
13. Handley C.J., Winter G.M., Ilic M.Z., Ross J.M., Anthony Poole C., and Clem Robinson H. Distribution of newly synthesized aggrecan in explant cultures of bovine cartilage treated with retinoic acid. Matrix Biol. 21 (2002) 579-592
14. Hardingham T.E., Fosang A.J., and Dudhia J. The structure, function and turnover of aggrecan, the large aggregating proteoglycan from cartilage. Eur. J. Clin. Chem. Clin. Biochem. 32 (1994) 249-257
15. Hughes C.E., Caterson B., Fosang A.J., Roughley P.J., and Mort J.S. Monoclonal antibodies that specifically recognize neoepitope sequences generated by 'aggrecanase' and matrix metalloproteinase cleavage of aggrecan: application to catabolism in situ and in vitro. Biochem. J. 305 (1995) 799-804
16. Hughes C.E., Little C.B., Buttner F.H., Bartnik E., and Caterson B. Differential expression of aggrecanase and matrix metalloproteinase activity in chondrocytes isolated from bovine and porcine articular cartilage. J. Biol. Chem. 273 (1998) 30576-30582
17. Hutchinson J.W., Tierney G.M., Parsons S.L., and Davis T.R. Dupuytren's disease and frozen shoulder induced by treatment with a matrix metalloproteinase inhibitor. J. Bone Jt. Surg., Br. 80 (1998) 907-908
18. Ilic M.Z., Carter P., Tyndall A., Dudhia J., and Handley C.J. Proteoglycans and catabolic products of proteoglycans present in ligament. Biochem. J. 385 (2005) 381-388
19. Jones L., Ghaneh P., Humphreys M., and Neoptolemos J.P. The matrix metalloproteinases and their inhibitors in the treatment of pancreatic cancer. Ann. N. Y. Acad. Sci. 880 (1999) 288-307
20. Kaushal G.P., and Shah S.V. The new kids on the block: ADAMTSs, potentially multifunctional metalloproteinases of the ADAM family. J. Clin. Invest. 105 (2000) 1335-1337
21. Little C.B., Flannery C.R., Hughes C.E., Mort J.S., Roughley P.J., Dent C., and Caterson B. Aggrecanase versus matrix metalloproteinases in the catabolism of the interglobular domain of aggrecan in vitro. Biochem. J. 344 (1999) 61-68
22. Little C.B., Hughes C.E., Curtis C.L., Janusz M.J., Bohne R., Wang-Weigand S., Taiwo Y.O., Mitchell P.G., Otterness I.G., Flannery C.R., and Caterson B. Matrix metalloproteinases are involved in C-terminal and interglobular domain processing of cartilage aggrecan in late stage cartilage degradation. Matrix Biol. 21 (2002) 271-288
23. McCawley L.J., and Matrisian L.M. Matrix metalloproteinases: multifunctional contributors to tumor progression. Mol. Med. Today 6 (2000) 149-156
24. Porter S., Clark I.M., Kevorkian L., and Edwards D.R. The ADAMTS metalloproteinases. Biochem. J. 386 (2005) 15-27
25. Primakoff P., and Myles D.G. The ADAM gene family: surface proteins with adhesion and protease activity. Trends Genet. 16 (2000) 83-87
26. Ralphs J.R., Benjamin M., and Thornett A. Cell and matrix biology of the suprapatella in the rat: a structural and immunocytochemical study of fibrocartilage in a tendon subject to compression. Anat. Rec. 231 (1991) 167-177
27. Rees S.G., Flannery C.R., Little C.B., Hughes C.E., Caterson B., and Dent C.M. Catabolism of aggrecan, decorin and biglycan in tendon. Biochem. J. 350 (2000) 181-188
28. Rees S.G., Davies J.R., Tudor D., Flannery C.R., Hughes C.E., Dent C.M., and Caterson B. Immunolocalisation and expression of proteoglycan 4 (cartilage superficial zone proteoglycan) in tendon. Matrix Biol. 21 (2002) 593-602
29. Rees S.G., Curtis C.L., Dent C.M., and Caterson B. Catabolism of aggrecan proteoglycan aggregate components in short-term explant cultures of tendon. Matrix Biol. 24 (2005) 219-231
30. Riley G.P., Harrall R.L., Constant C.R., Chard M.D., Cawston T.E., and Hazleman B.L. Glycosaminoglycans of human rotator cuff tendons: changes with age and in chronic rotator cuff tendinitis. Ann. Rheum. Dis. 53 (1994) 367-376
31. Samiric T., Ilic M.Z., and Handley C.J. Large aggregating and small leucine-rich proteoglycans are degraded by different pathways and at different rates in tendon. Eur. J. Biochem. 271 (2004) 3612-3620
32. Samiric T., Ilic M.Z., and Handley C.J. Characterisation of proteoglycans and their catabolic products in tendon and explant cultures of tendon. Matrix Biol. 23 (2004) 127-140
33. Sandy J.D., Flannery C.R., Neame P.J., and Lohmander L.S. The structure of aggrecan fragments in human synovial fluid. Evidence for the involvement in osteoarthritis of a novel proteinase which cleaves the Glu 373-Ala 374 bond of the interglobular domain. J. Clin. Invest. 89 (1992) 1512-1516
34. Sztrolovics R., White R.J., Poole A.R., Mort J.S., and Roughley P.J. Resistance of small leucine-rich repeat proteoglycans to proteolytic degradation during interleukin-1-stimulated cartilage catabolism. Biochem. J. 339 (1999) 571-577
35. Sztrolovics R., Recklies A.D., Roughley P.J., and Mort J.S. Hyaluronate degradation as an alternative mechanism for proteoglycan release from cartilage during interleukin-1beta-stimulated catabolism. Biochem. J. 362 (2002) 473-479
36. Sztrolovics R., White R.J., Roughley P.J., and Mort J.S. The mechanism of aggrecan release from cartilage differs with tissue origin and the agent used to stimulate catabolism. Biochem. J. 362 (2002) 465-472
37. Tierney G.M., Griffin N.R., Stuart R.C., Kasem H., Lynch K.P., Lury J.T., Brown P.D., Millar A.W., Steele R.J., and Parsons S.L. A pilot study of the safety and effects of the matrix metalloproteinase inhibitor marimastat in gastric cancer. Eur. J. Cancer 35 (1999) 563-568
38. Tsuzaki M., Guyton G., Garrett W., Archambault J.M., Herzog W., Almekinders L., Bynum D., Yang X., and Banes A.J. IL-1 beta induces COX2, MMP-1,-3 and-13, ADAMTS-4, IL-1 beta and IL-6 in human tendon cells. J. Orthop. Res. 21 (2003) 256-264
39. Vogel K.G. The effect of compressive loading on proteoglycan turnover in cultured fetal tendon. Connect. Tissue Res. 34 (1996) 227-237
40. Vogel K.G. What happens when tendons bend and twist? Proteoglycans. J. Musculoskelet Neuronal. Interact. 4 (2004) 202-203
41. Vogel K.G., and Heinegard D. Characterization of proteoglycans from adult bovine tendon. J. Biol. Chem. 260 (1985) 9298-9306
42. Vogel K.G., Paulsson M., and Heinegard D. Specific inhibition of type I and type II collagen fibrillogenesis by the small proteoglycan of tendon. Biochem. J. 223 (1984) 587-597
43. Vogel K.G., Keller E.J., Lenhoff R.J., Campbell K., and Koob T.J. Proteoglycan synthesis by fibroblast cultures initiated from regions of adult bovine tendon subjected to different mechanical forces. Eur. J. Cell Biol. 41 (1986) 102-112
44. Vogel K.G., Ordog A., Pogany G., and Olah J. Proteoglycans in the compressed region of human tibialis posterior tendon and in ligaments. J. Orthop. Res. 11 (1993) 68-77
45. Vogel K.G., Sandy J.D., Pogany G., and Robbins J.R. Aggrecan in bovine tendon. Matrix Biol. 14 (1994) 171-179
46. Vogel K.G., Evanko S., and Robbins J.R. What proteoglycan content says about the mechanical history of tendon. In: Archer C.W., Caterson B., Benjamin M., and Ralphs J.R. (Eds). Biology of the Synovial Joint (1999), Harwood Academic Publishers 301-313
47. Waggett A.D., Ralphs J.R., Kwan A.P., Woodnutt D., and Benjamin M. Characterization of collagens and proteoglycans at the insertion of the human Achilles tendon. Matrix Biol. 16 (1998) 457-470
48. Wojtowicz-Praga S., Torri J., Johnson M., Steen V., Marshall J., Ness E., Dickson R., Sale M., Rasmussen H.S., Chiodo T.A., and Hawkins M.J. Phase I trial of Marimastat, a novel matrix metalloproteinase inhibitor, administered orally to patients with advanced lung cancer. J. Clin. Oncol. 16 (1998) 2150-2156